Total Payments
$17,146
2023 Payments
$1,969
Companies
8
Transactions
55
Payment Breakdown by Category
Research$16,889 (98.5%)
Food & Beverage$257.00 (1.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $16,889 | 50 | 98.5% |
| Food and Beverage | $257.00 | 5 | 1.5% |
Payments by Type
Research
$16,889
50 transactions
General
$257.00
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Orexo US, Inc. | $7,500 | 3 | $0 (2023) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $3,784 | 20 | $0 (2022) |
| Supernus Pharmaceuticals, Inc. | $2,293 | 11 | $0 (2019) |
| Biogen, Inc. | $1,487 | 7 | $0 (2018) |
| Teva Pharmaceuticals USA, Inc. | $1,121 | 8 | $0 (2020) |
| Eli Lilly and Company | $864.75 | 3 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $54.70 | 1 | $0 (2023) |
| Lundbeck LLC | $40.36 | 2 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $1,969 | 5 | Orexo US, Inc. ($1,500) |
| 2022 | $497.19 | 2 | Eli Lilly and Company ($450.00) |
| 2021 | $6,000 | 1 | Orexo US, Inc. ($6,000) |
| 2020 | $1,121 | 8 | Teva Pharmaceuticals USA, Inc. ($1,121) |
| 2019 | $6,031 | 30 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($3,737) |
| 2018 | $1,487 | 7 | Biogen, Inc. ($1,487) |
| 2017 | $40.36 | 2 | Lundbeck LLC ($40.36) |
All Payment Transactions
55 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/06/2023 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $114.75 | General |
| 06/02/2023 | Orexo US, Inc. | — | — | Cash or cash equivalent | $1,000.00 | Research |
| Study: OXD01-001 | ||||||
| 06/02/2023 | Orexo US, Inc. | — | — | Cash or cash equivalent | $500.00 | Research |
| Study: OXD01-001 | ||||||
| 04/20/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $54.70 | General |
| 01/31/2023 | Eli Lilly and Company | — | — | In-kind items and services | $300.00 | Research |
| Study: A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | ||||||
| 06/01/2022 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Food and Beverage | In-kind items and services | $47.19 | General |
| 04/29/2022 | Eli Lilly and Company | — | — | In-kind items and services | $450.00 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | ||||||
| 08/19/2021 | Orexo US, Inc. | — | — | Cash or cash equivalent | $6,000.00 | Research |
| Study: OXD01-001 | ||||||
| 02/08/2020 | Teva Pharmaceuticals USA, Inc. | AJOVY (Biological) | — | In-kind items and services | $253.13 | Research |
| Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Followed by an Open-Label Extension to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder • Category: Central Nervous System | ||||||
| 02/08/2020 | Teva Pharmaceuticals USA, Inc. | AJOVY (Biological) | — | In-kind items and services | $74.55 | Research |
| Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Followed by an Open-Label Extension to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder • Category: Central Nervous System | ||||||
| 02/08/2020 | Teva Pharmaceuticals USA, Inc. | AJOVY (Biological) | — | In-kind items and services | $59.91 | Research |
| Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Followed by an Open-Label Extension to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder • Category: Central Nervous System | ||||||
| 02/08/2020 | Teva Pharmaceuticals USA, Inc. | AJOVY (Biological) | — | In-kind items and services | $29.95 | Research |
| Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Followed by an Open-Label Extension to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder • Category: Central Nervous System | ||||||
| 02/08/2020 | Teva Pharmaceuticals USA, Inc. | AJOVY (Biological) | — | In-kind items and services | $29.95 | Research |
| Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Followed by an Open-Label Extension to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder • Category: Central Nervous System | ||||||
| 02/07/2020 | Teva Pharmaceuticals USA, Inc. | AJOVY (Biological) | — | In-kind items and services | $169.73 | Research |
| Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Followed by an Open-Label Extension to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder • Category: Central Nervous System | ||||||
| 02/06/2020 | Teva Pharmaceuticals USA, Inc. | AJOVY (Biological) | — | In-kind items and services | $356.80 | Research |
| Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Followed by an Open-Label Extension to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder • Category: Central Nervous System | ||||||
| 02/06/2020 | Teva Pharmaceuticals USA, Inc. | AJOVY (Biological) | — | In-kind items and services | $146.85 | Research |
| Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Followed by an Open-Label Extension to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder • Category: Central Nervous System | ||||||
| 12/30/2019 | Supernus Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $14.71 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD | ||||||
| 12/16/2019 | Supernus Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $6.10 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD | ||||||
| 11/20/2019 | Supernus Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $7.32 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD | ||||||
| 11/20/2019 | Supernus Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $2.84 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD | ||||||
| 11/08/2019 | Supernus Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $7.29 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD | ||||||
| 10/28/2019 | Supernus Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $96.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD | ||||||
| 10/21/2019 | Supernus Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $708.28 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD | ||||||
| 10/21/2019 | Supernus Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $240.76 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD | ||||||
| 10/21/2019 | Supernus Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $137.18 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| OXD01-001 | Orexo US, Inc. | $7,500 | 3 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD | Supernus Pharmaceuticals, Inc. | $2,293 | 11 |
| A Phase 2, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BIIB104 in Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS) | Biogen, Inc. | $1,487 | 7 |
| Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD | Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,289 | 6 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BREXPIPRAZOLE AS ADJUNCTIVE THERAPY IN THE MAINTENANCE TREATMENT OF ADULTS WITH MAJOR DEPRESSIVE DISORDER. | Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,238 | 7 |
| A PHASE IIIB MULTI-CENTER, OPEN-LABEL, MIRROR-IMAGE, STUDY IN ADULT SUBJECTS WITH SCHIZOPHRENIA TREATED PROSPECTIVELY FOR 6-MONTHS WITH ABILIFY MYCITE | Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,210 | 6 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Followed by an Open-Label Extension to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder | Teva Pharmaceuticals USA, Inc. | $1,121 | 8 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $450.00 | 1 |
| A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | Eli Lilly and Company | $300.00 | 1 |
About Dr. Eric Chavez, MD
Dr. Eric Chavez, MD is a Psychiatry healthcare provider based in San Diego, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1902813157.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Eric Chavez, MD has received a total of $17,146 in payments from pharmaceutical and medical device companies, with $1,969 received in 2023. These payments were reported across 55 transactions from 8 companies. The most common payment nature is "" ($16,889).
Ad
Practice Information
- Specialty Psychiatry
- Other Specialties Psychiatry, Addiction Medicine
- Location San Diego, CA
- Active Since 08/01/2006
- Last Updated 10/10/2014
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1902813157
Products in Payments
- ABILIFY MYCITE (Drug) $1,210
- AJOVY (Biological) $1,121
- TRINTELLIX (Drug) $40.36
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in San Diego
Dr. Jonathan Meyer, M.d, M.D
Psychiatry — Payments: $2.0M
Psychiatry $2.0M
Dr. Sanjai Rao, M.d, M.D
Psychiatry — Payments: $633,149
Psychiatry $633,149
Dr. Murray Stein, M.d., M.p.h, M.D., M.P.H
Psychiatry — Payments: $115,110
Psychiatry $115,110
Dr. Mukesh Sanghadia, M.d., Mrcpsych(Uk), M.D., MRCPSYCH(UK)
Psychiatry — Payments: $82,626
Psychiatry $82,626
Dr. Neil Richtand, M.d, M.D
Psychiatry — Payments: $76,458
Psychiatry $76,458
Clark Smith, Md, MD
Psychiatry — Payments: $72,261
Psychiatry $72,261